Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis — Subgroup Analyses of the CALIPSO Trial

INTRODUCTION: Coronary artery calcium (CAC) is highly prevalent and linked with poor outcomes in patients receiving maintenance hemodialysis, and its reduction may improve patient prognosis. SNF472, a selective inhibitor of hydroxyapatite crystallization, slows CAC progression in patients receiving...

Descripción completa

Detalles Bibliográficos
Autores principales: Raggi, Paolo, Bellasi, Antonio, Sinha, Smeeta, Bover, Jordi, Rodriguez, Mariano, Ketteler, Markus, Bushinsky, David A., Garg, Rekha, Perelló, Joan, Gold, Alex, Chertow, Glenn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710828/
https://www.ncbi.nlm.nih.gov/pubmed/33305110
http://dx.doi.org/10.1016/j.ekir.2020.09.032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710828/
https://www.ncbi.nlm.nih.gov/pubmed/33305110
http://dx.doi.org/10.1016/j.ekir.2020.09.032

Ejemplares similares